Five Arrows invests in Implicity
Funding Provisional 86% confidence first seen
Implicity raised €35M in growth funding, with IRIS and Five Arrows (in association/lead investor capacity) investing to scale its AI platform for cardiac monitoring. The article says the funding round is tied to a reported 26% reduction in patient mortality and will be used to expand in the United States, build teams in the US and Germany, and pursue acquisitions of smaller firms rather than taking a majority stake. This matters because it supports scaling clinically validated AI in remote cardiac monitoring while strengthening Implicity’s ability to enter and grow in regulated, hard-to-access healthcare markets.
The deal
Implicity €35M Other · announced 9 Sep 2026
Investors IRIS Five Arrows
Deal terms as reported in the coverage below.
Decision brief
- What changed
- Implicity raised €35 million in growth funding from IRIS and Five Arrows to scale its AI platform for cardiac monitoring. According to the coverage, the company plans to use the funding to expand in the United States, add teams in the US and Germany, and pursue acquisitions of smaller firms.
- Why it matters
- For healthcare and AI leaders, this signals new capital behind a clinically positioned remote cardiac monitoring platform that the coverage links to a reported 26% reduction in patient mortality. That combination of funding and claimed clinical impact can strengthen Implicity’s ability to compete in regulated markets, expand commercial operations internationally, and potentially consolidate adjacent capabilities through acquisitions.
- Evidence
- The event is supported by one report from Tech Funding News AI stating that Implicity raised €35 million from IRIS and Five Arrows and tying the round to a reported 26% reduction in patient mortality, as well as planned US expansion, hiring, and acquisitions. Because the coverage comes from a single outlet, independent confirmation and additional reporting consistency are limited.
- What remains uncertain
- The article does not detail the underlying clinical study, regulatory status, revenue traction, valuation, or the exact investment roles and terms beyond naming IRIS and Five Arrows, so the strength and transferability of the reported mortality benefit should be treated as unverified from this coverage alone. It is also unclear how quickly US expansion and acquisitions will occur or whether they will materially improve market access and growth.
- Monitor next
- Watch for concrete disclosures on US market expansion, such as announced hires, regulatory milestones, provider partnerships, or acquisition targets following the funding round.
Analytical support, not advice — assumptions and open questions stated above.